Objective: Prognostic information known preoperatively allows stratification of patients to surgery; induction therapy and surgery; or definitive chemoradiotherapy and may prevent a futile thoracotomy. Attention has focussed on the standard uptake value (SUV) of the primary tumour but less has been described regarding the 18 F-fluoro-2-deoxy-D-glucose ( 18 F-FDG) avidity of mediastinal nodes. We aimed, in a group of surgically resected cN0-1 but pN2 tumours, to compare the survival of patients with and without 18 F-FDG avid mediastinal nodes. Methods: Retrospective review of a surgical database identified cN0-1 non-small-cell lung cancer (NSCLC) patients with pN2 disease after resection. Survival of non-FDG avid N2 versus FDG avid N2 groups was compared after stratification according to variables found on univariate analysis to affect survival. Results: From January 1993 to December 2006, 42 patients were identified; 27 (64%) had non-FDG avid N2 disease. Five-year and median survival were better in the non-FDG avid N2 disease group, 25% versus 0% and 30 (16-44) versus 13 (10-16) months, respectively ( p = 0.02). After 1998, the difference in survival was 41% versus 0% and 35 (14-56) versus 12 (16-18) months, respectively ( p = 0.02). Conclusions: After resection, patients with non-FDG avid N2 disease have better survival than patients with FDG avid N2 disease. Exploratory thoracotomy alone (after frozen section analysis) cannot be advocated in patients with non-FDG avid N2 disease as survival after resection appears at least equivalent to alternate therapeutic approaches in this group. This assertion may be tempered if right pneumonectomy is required or R0 resection is unachievable. Mediastinal nodal avidity may improve stratification in future studies of long-term survival in NSCLC. Crown
Introduction
Mountain's seminal article outlining the 1997 staging system for non-small-cell lung cancer (NSCLC) brought into clear focus the different outcomes for patients staged clinically (cTNM) and after operation (pTNM) [1] . Mediastinal nodal (N2) disease identified preoperatively (cN2) has a significantly worse prognosis than when identified postoperatively (pN2). This distinction has been most important in allowing different treatments to be compared when applied to uniformly staged patients. The concept has been further distilled by investigators attempting to bring clarity to communication regarding N2 disease and its appropriate management when discovered intra-operatively. Interestingly, frozen section analysis classifies 'surprise' or 'unanticipated' involved N2 nodes as cN2 and, if resection is completed, final pathology classifies the same nodes as pN2 (variously termed 'unsuspected', 'incidental', 'underappreciated' or 'ignored' N2 disease) [2] .
The great difficulty with the finding of N2 disease at operation or on pathological specimens is that patients have already undergone thoracotomy with its attendant morbidity and mortality. By contrast, prognostic information known preoperatively allows avoidance of a futile thoracotomy or indeed stratification of patients to those who may benefit most from preoperative chemotherapy.
Many authors have focussed their attention upon the standard uptake value (SUV) of the primary tumour as measured by [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] F-fluoro-2-deoxy-D-glucose ( 18 F-FDG) positron emission tomography (PET) when attempting to predict outcome [3, 4] , but little has been described with respect to stratification of pN2 disease based specifically on the 18 F-FDG avidity of mediastinal nodes.
We propose a new term 'non-FDG avid N2 disease' to describe PET negative microscopic N2 disease (i.e., patients with cN0-1 after careful preoperative staging and pN2 disease on final pathology whose preoperative PET scan is negative in the mediastinum). The aim of this study was, in a group of surgically resected cN0-1 and pN2 patients, to compare the long-term survival of patients with non-FDG avid N2 disease to those with 18 F-FDG avid mediastinal lymph nodes.
Materials and methods
Using Institutional Review Board (IRB) waiver provisions of our institutional audit, we undertook a retrospective review of a prospectively maintained single institution database, supplemented by chart review and telephone interview as necessary. Patients undergoing lung resection with curative intent for NSCLC between January 1993 and December 2006 with cN0-1 staging in whom final pathology revealed pN2 disease were identified. Patients who received preoperative chemotherapy were excluded. Clinical nodal status was assessed using computed tomography (CT) and PET scan in all patients. Mediastinoscopy was undertaken in patients with enlarged mediastinal lymph nodes. Of note, mediastinal FDG avidity did not mandate mediastinoscopy. PET data were not included when calculating the final clinical stage. Patients received mediastinal lymph node dissection or systematic sampling based on surgeon preference. The database was locked and analysis undertaken on 28 February 2008.
PET scan status of the N2 nodes was determined by review of original final PET scan report. Of note, during the study period, PET technology changed considerably. Initially qualitative assessment, then quantitative assessment (using an SUV threshold of 2.5), then software to co-register CT and PET images, and finally dedicated PET/CT scanners were used. Pathological nodal status was determined by review of original final pathology report. Haematoxylin and eosin staining was used to assess sections of nodal tissue without analysis of cytokeratins. N2 disease was defined using the AJCC 1997 staging system [1, 5] . Patients were divided in to two groups: false-negative N2 nodes on PET scan (non-FDG avid N2 disease) and true positive N2 nodes on PET scan ( 18 F-FDG avid N2 disease). The groups were compared with respect to age, sex, year of resection, operation performed, T stage, histology, histological grade, rate of R0 resection, postoperative complications, in-hospital mortality and longterm survival. R0 resection was defined as a negative microscopic margin of the primary tumour without requirement of absence of extra-nodal spread or the highest node resected to be negative for carcinoma. In-hospital mortality included deaths occurring after discharge but within 30 days of operation.
Chi-square or Fisher's exact test was used as appropriate for categorical variables. A univariate analysis of survival was undertaken to identify all variables potentially affecting survival. Kaplan-Meier curves were calculated to assess survival and compared using the log rank test.
Due to the small number of subjects, multivariate analysis was not undertaken. Rather, the two groups were compared after stratification, according to variables found to be significant on univariate analysis, to allow hypothesis generation.
Results
Eighty-nine consecutive patients with cN0-1 and pN2 disease were identified, of whom 46 had undergone PET scanning. One patient in the first year of the study was found on PET to have metastatic disease, but clinicians were at this time blinded to the PET results. This patient was excluded from analysis. Three PET scans were undertaken at an outside institution and were not available for review. Thus, 42 patients were available for analysis and form the basis of this report.
Twenty-seven patients (64%) had non-FDG avid N2 disease and 15 (36%) had 18 F-FDG avid N2 disease. There was no significant difference between the groups with respect to categorical variables (Table 1) . Median follow-up was 18.5 months.
On univariate analysis, 5-year and median survival were significantly better in the non-FDG avid N2 disease group, 25% versus 0% and 30 (16-44) versus 13 (10-16) months, respectively ( p = 0.02) (Fig. 1 ). Other variables found, on univariate analysis, to affect survival included right pneumonectomy, pneumonectomy, T stage, grade and resection prior to the year 1999 (Table 2) .
When patients were stratified according to right pneumonectomy ( Fig. 2) , pneumonectomy, T stage and year of study ( Fig. 3) , the superior survival in the non-FDG avid N2 disease group was maintained. For example, the difference in 5-year and median survival according to non-FDG avid N2 (Fig. 2) . In the three patients undergoing right pneumonectomy, all had non-FDG avid N2 disease and survival was poor, equalling only 0, 5 and 30 months. In patients undergoing resection after 1998, the difference in 5-year and median survival according to non-FDG avid N2 disease status was 41% versus 0% and 35 (14-56) versus 12 (16) (17) (18) months, respectively ( p = 0.02) (Fig. 3) . In patients resected after 1998, achieving R0 resection differences in 5-year and median survival according to non-FDG avid N2 disease status were 44% versus 0% and 46 (25-67) versus 13 (11) (12) (13) (14) (15) months, respectively ( p < 0.01).
Difference in survival between the two groups was not significantly different when stratified according to grade.
Discussion
Survival of patients with resected NSCLC and metastasis to mediastinal lymph nodes is poor, with 5-year survival ranging from 13% to 42% [1, 6] . N2 disease diagnosed clinically (cN2) has a worse prognosis than when found after resection (pN2) [1] . Improved survival of patients with cN2 disease treated with chemotherapy prior to surgery [7, 8] , and the equivalence of definitive chemoradiotherapy to chemotherapy plus surgery in this group of patients [9] [10] [11] has encouraged some investigators to undertake aggressive staging (including thoracotomy) to exclude patients from surgical resection. Such an approach confuses the outcome of cN2 disease with that of pN2 disease. For example, to quote an expected 5-year survival of 42% prior to planned surgical resection and postoperative adjuvant chemotherapy for a patient with known N2 disease (cN2) on the basis of results achieved by Douillard et al. (in patients with pN2 disease) is misleading [6] . In contradistinction, to expect survival of only 15% after resection and adjuvant chemotherapy for a patient with a presumed negative mediastinum after careful evaluation including bronchoscopy, CT scan and PET scan (cN0-1) and found on intra-operative frozen section to have involved mediastinal nodes (non-FDG avid N2 disease) justified on the basis of results achieved by Vansteenkiste et al. (in patients with cN2 disease) is similarly ill informed [12] .
Rather, patients who require thoracotomy and mediastinal sampling to identify minimal N2 disease in fact represent a group of patients who may be better categorised as having pN2 disease (and indeed by definition would be so classified if resection were undertaken and N2 involvement assessed on final pathology). With the advent of the widespread use of effective chemotherapy, this group can realistically hope for survival in the order of 42% [6, 13] .
At our institution, adjuvant platinum-based chemotherapy in patients with N2 disease was standard in the latter half of the study period. This may explain the trend towards [15] . These results support our finding of a significantly better survival in the patients with non-FDG avid N2 disease. By contrast, Sasaki et al. retrospectively studied a heterogeneous group of 162 patients ranging in stage from IA to IIIB, treated with either surgery or definitive radiotherapy and found the SUV max of the regional lymph nodes (when treated as a categorical variable using a cut point of 5) was not predictive of overall survival [16] . In our study, PET scan effectively stratified cN0-1 patients 'prior to thoracotomy' to an 18 F-FDG avid group with outcomes similar to historical cN2 patients and a group with non-FDG avid N2 disease and outcomes similar to historical carefully preoperatively staged pN2 patients treated with resection. Our 18 F-FDG avid group represents patients with false-negative mediastinoscopy or possibly with 'ignored N2 disease'. Their 5-year survival (Fig. 1) of 0% is worse even than patients with cN2 disease undergoing resection, which ranges from 7% to 15% [2] . Such an outcome implies PET scan has correctly identified preoperatively a subset of patients with pN2 disease and very poor prognosis. These findings argue strongly for more extensive mediastinal staging in patients with positive PET scans and negative mediastinoscopy (particularly when an alternative histological diagnosis explaining the 18 F-FDG avidity is not found) in the hope of identifying N2 disease preoperatively, avoiding resection and rather treating such patients with definitive chemoradiotherapy or induction therapy, restaging and resection in patients, who have not advanced on treatment. The approach of surgery followed by chemotherapy in patients with cN2 disease is not well tested in the literature.
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The 5-year survival of our patients with non-FDG avid N2 disease was 25% (Fig. 1 ) and similar to series of patients with pN2 disease which averages 27% (range: 14-43) [2] . Further, the 5-year survival of our patients with non-FDG avid N2 disease in the latter half of the series when adjuvant platinum-based chemotherapy was routine at our institution was 41% (Fig. 3) and compares favourably to patients with cN2 disease treated with induction chemotherapy 10-36% [7] [8] [9] [10] [17] [18] [19] , cN2 disease treated with definitive chemoradiotherapy 14-15% [9, 10, [19] [20] [21] or pN2 disease treated with surgery and adjuvant chemotherapy 42% [6] . In short, there does not appear to be superior outcome with any alternate treatment were such patients to be closed after only an exploratory thoracotomy proving microscopic N2 disease.
A caveat to our statement advocating surgical resection in patients with non-FDG avid N2 disease is the qualification that an R0 resection must be expected and the need for right pneumonectomy must be carefully weighed. Detterbeck, when considering the appropriateness of resection for 'surprise N2 disease', has argued convincingly that neither quality of life (loss of pulmonary function vs loss of hope) nor perioperative mortality of an exploratory thoracotomy is demonstrably different from that of a lobectomy [2] . The same cannot be argued when right pneumonectomy is undertaken. The small number of patients undergoing right pneumonectomy in our series makes it difficult to draw meaningful conclusions. Even so, in the subgroup of patients with non-FDG avid N2 disease requiring right pneumonectomy, perioperative mortality and, potentially, the association with more oncologically advanced disease, as well as the long-term physiological insult of the procedure combined to result in no 5-year survivors. In our series, as in the literature, resection less than R0 was not associated with meaningful long-term survival [2] . Indeed, rates of perioperative mortality after right pneumonectomy ranging in the literature from 0% to 16% [2] may tip the scales (after intra-operative frozen section and documentation of N2 disease) in favour of exploratory thoracotomy alone and alternative therapy (definitive chemoradiotherapy or induction therapy, restaging and subsequent resection) in patients in whom a right pneumonectomy is necessary to achieve an R0 resection.
The literature regarding alternate treatment strategies and their effect on long-term survival in N2 NSCLC pre-dates the now-widespread use of PET scanning in staging NSCLC. At our institution, the rate of false-negative PET scan is 2% [22] . It is this group of patients in whom intra-operative assessment of mediastinal nodes will discern non-FDG avid N2 disease. It would be wrong to exclude these patients from surgical resection as their long-term survival is in the order of the best outcomes for patients treated with either induction chemotherapy or combined chemoradiotherapy (CRT) with curative intent.
Rates of false-negative PET scan vary widely [23, 24] , possibly in part due to institutional differences in scanning [25] and in part to the prevalence of mediastinal nodal disease in various populations. This potentially limits the general applicability of our findings and mandates clinicians are aware of the sensitivity and specificity of PET scanning in their own institution, as well as the pre-test probability of mediastinal nodal involvement in a particular patient which is, in turn, predicated upon the prevalence of disease (including granulomatous) within their clinical population.
Limitations of our study are typical of a retrospective review and include the selective use of mediastinoscopy, nodal sampling, nodal dissection, adjuvant chemotherapy and radiotherapy. The small sample size and retrospective nature of our review mandate our findings be viewed as exploratory and larger multi-institution studies, allowing multivariate analysis of data be undertaken before any finding can be broadly applied.
Within the limits of this study, non-FDG avid N2 disease treated with resection had rates of long-term survival superior to historical series of cN2 disease treated with surgery alone or induction therapy and surgery and outcomes equivalent to the best results for patients with pN2 disease treated with adjuvant chemotherapy. At our institution, in the current era of effective platinum-based chemotherapy, non-therapeutic thoracotomy cannot be advocated in carefully staged cN0-1 patients with a negative PET scan in the mediastinum, regardless of intra-operative frozen section analysis of N2 nodes. An exception to this assertion is the group of patients requiring right pneumonectomy in whom potentially higher rates of perioperative mortality may favour intra-operative frozen section and exploration alone when involved N2 nodes are found. PET scanning, including mediastinal nodal avidity, ought to be part of stratification in future studies of long-term survival in NSCLC.
